Green tea polyphenols in drug discovery: A success or failure?

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Green tea is made from unfermented dried leaves from Camellia sinensis and has been consumed by humans for thousands of years. For nearly as long, it has been used as a folk remedy for a wide array of diseases. More recently, a large number of in vitro and in vivo scientific studies have supported this ancient contention that the polyphenols from green tea can provide a number of health benefits. As these compounds are clearly safe for human consumption and ubiquitous in the food supply, they are highly attractive as lead compounds for drug discovery programs. However, as drugs, they are far from optimum. They are relatively unstable, poorly absorbed, and readily undergo a number of metabolic transformations by intestinal microbiota and human enzymes. Further, as these compounds target a wide array of biological systems, in vivo testing is rather difficult as effects on alternative pathways need to be carefully eliminated. The purpose of this review is to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery.

Original languageEnglish (US)
Pages (from-to)589-595
Number of pages7
JournalExpert Opinion on Drug Discovery
Volume6
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Polyphenols
Tea
Drug Discovery
Camellia sinensis
Food Supply
Traditional Medicine
Insurance Benefits
Enzymes
Pharmaceutical Preparations

Keywords

  • catechins
  • drug discovery
  • green tea
  • insulin
  • polyphenols

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Green tea polyphenols in drug discovery : A success or failure? / Smith, Thomas.

In: Expert Opinion on Drug Discovery, Vol. 6, No. 6, 06.2011, p. 589-595.

Research output: Contribution to journalArticle

@article{2c2db0a0261b4b05847f0f336d570d19,
title = "Green tea polyphenols in drug discovery: A success or failure?",
abstract = "Green tea is made from unfermented dried leaves from Camellia sinensis and has been consumed by humans for thousands of years. For nearly as long, it has been used as a folk remedy for a wide array of diseases. More recently, a large number of in vitro and in vivo scientific studies have supported this ancient contention that the polyphenols from green tea can provide a number of health benefits. As these compounds are clearly safe for human consumption and ubiquitous in the food supply, they are highly attractive as lead compounds for drug discovery programs. However, as drugs, they are far from optimum. They are relatively unstable, poorly absorbed, and readily undergo a number of metabolic transformations by intestinal microbiota and human enzymes. Further, as these compounds target a wide array of biological systems, in vivo testing is rather difficult as effects on alternative pathways need to be carefully eliminated. The purpose of this review is to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery.",
keywords = "catechins, drug discovery, green tea, insulin, polyphenols",
author = "Thomas Smith",
year = "2011",
month = "6",
doi = "10.1517/17460441.2011.570750",
language = "English (US)",
volume = "6",
pages = "589--595",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Green tea polyphenols in drug discovery

T2 - A success or failure?

AU - Smith, Thomas

PY - 2011/6

Y1 - 2011/6

N2 - Green tea is made from unfermented dried leaves from Camellia sinensis and has been consumed by humans for thousands of years. For nearly as long, it has been used as a folk remedy for a wide array of diseases. More recently, a large number of in vitro and in vivo scientific studies have supported this ancient contention that the polyphenols from green tea can provide a number of health benefits. As these compounds are clearly safe for human consumption and ubiquitous in the food supply, they are highly attractive as lead compounds for drug discovery programs. However, as drugs, they are far from optimum. They are relatively unstable, poorly absorbed, and readily undergo a number of metabolic transformations by intestinal microbiota and human enzymes. Further, as these compounds target a wide array of biological systems, in vivo testing is rather difficult as effects on alternative pathways need to be carefully eliminated. The purpose of this review is to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery.

AB - Green tea is made from unfermented dried leaves from Camellia sinensis and has been consumed by humans for thousands of years. For nearly as long, it has been used as a folk remedy for a wide array of diseases. More recently, a large number of in vitro and in vivo scientific studies have supported this ancient contention that the polyphenols from green tea can provide a number of health benefits. As these compounds are clearly safe for human consumption and ubiquitous in the food supply, they are highly attractive as lead compounds for drug discovery programs. However, as drugs, they are far from optimum. They are relatively unstable, poorly absorbed, and readily undergo a number of metabolic transformations by intestinal microbiota and human enzymes. Further, as these compounds target a wide array of biological systems, in vivo testing is rather difficult as effects on alternative pathways need to be carefully eliminated. The purpose of this review is to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery.

KW - catechins

KW - drug discovery

KW - green tea

KW - insulin

KW - polyphenols

UR - http://www.scopus.com/inward/record.url?scp=79957542707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957542707&partnerID=8YFLogxK

U2 - 10.1517/17460441.2011.570750

DO - 10.1517/17460441.2011.570750

M3 - Article

AN - SCOPUS:79957542707

VL - 6

SP - 589

EP - 595

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 6

ER -